Powell speech takes center stage in Tuesday’s economic events
INVO Fertility, Inc. (NASDAQ:IVF) disclosed Friday that an institutional investor and existing holder of its Series C-2 Convertible Preferred Stock exercised an additional investment right on Monday to acquire 200 shares of C-2 Preferred for $200,000 in cash. The micro-cap company, currently valued at $3.19 million, has been facing significant financial challenges with a concerning current ratio of 0.11, indicating potential liquidity issues.
According to a statement based on the company’s SEC filing, the transaction was completed under the terms of a Securities Purchase Agreement initially dated January 3, 2024, and later joined by INVO Fertility on October 11, 2024. The preferred shares were issued at an aggregate stated value of $200,000.
As a result of the investment, the conversion price of the Series C-2 Preferred was adjusted to $0.6643 per share. The company stated that the preferred stock and the shares of common stock issuable upon conversion were sold in a private placement, relying on exemptions from registration under the Securities Act of 1933, specifically Section 4(a)(2) and Rule 506.
The company noted that further information required by Item 3.02 of Form 8-K is incorporated by reference from a previous filing made on July 1, 2025.
INVO Fertility is incorporated in Nevada and its common stock trades on The Nasdaq Stock Market LLC under the symbol IVF. The information in this article is based on a press release statement included in the company’s SEC filing.
In other recent news, INVO Fertility, Inc. has finalized a $6 million settlement with Dr. Elizabeth Pritts and the Elizabeth Pritts Revocable Living Trust, resolving litigation related to the company’s acquisition of the Wisconsin Fertility Institute. The company also announced an agreement with Five Narrow Lane LP to exchange a senior secured convertible debenture for Series C-2 Convertible Preferred Stock, effectively extinguishing the debenture. Additionally, INVO Fertility amended its Revenue Loan and Security Agreement with Decathlon Alpha V LP, involving a $1.5 million loan. In a move concerning its financial oversight, INVO Fertility’s board dismissed M&K CPAS, PLLC as its independent auditor, appointing WithumSmith+Brown, PC to audit the company’s financial statements for 2025. Furthermore, an institutional investor exercised its right to acquire $200,000 worth of Series C-2 Convertible Preferred Stock, adjusting the conversion price to $1.8909 per share. These developments reflect ongoing financial and operational adjustments at INVO Fertility.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.